Lomitapide must be used under the guidance of a physician, starting with a low dose and gradually adjusting, combined with the correct administration method, to ensure efficacy and reduce adverse reactions.

I. Dose Adjustment Regimen

1. Starting Dose

(1) The recommended starting dose is 5 mg once daily.

(2) All patients should start treatment at this lowest dose.

2. Dose Escalation Rules

(1) After two weeks of treatment, the dose may be increased to 10 mg based on the reduction in low-density lipoprotein cholesterol (LDL-C) and the patient's tolerability to the medication.

(2) Subsequent dose adjustments should be made at intervals of at least four weeks, sequentially increasing to 20 mg, 40 mg, with a maximum recommended dose of 60 mg daily.

3. Importance of Slow Titration

(1) The dose must be escalated gradually; skipping dose levels is not permitted.

(2) Slow titration helps reduce the frequency and severity of gastrointestinal adverse reactions and also decreases the risk of elevated liver enzymes.

4. Individualized Maintenance Dose

(1) The final maintenance dose may vary for each patient. The physician will determine the most appropriate individual dose based on the magnitude of LDL-C reduction, tolerability of side effects, and other factors.

(2) Do not adjust or discontinue the medication on your own.

II. Key Administration Instructions

1. Timing of Administration

(1) Take once daily, preferably at bedtime.

(2) Take on an empty stomach, and at least two hours after finishing the evening meal.

(3) Taking on an empty stomach at bedtime may reduce gastrointestinal discomfort.

2. How to Take

Swallow the capsule with a full glass of water. Do not chew or open the capsule.

3. Missed Dose

(1) If you miss a dose, take the normal dose at the regular time the next day.

(2) Do not take a double dose to make up for the missed dose.

4. Discontinuation Precautions

(1) If you stop taking lomitapide, cholesterol levels may rise again.

(2) Always consult your doctor before deciding to stop the medication.

III. Special Situations

1. Co-administration with Atorvastatin

(1) For patients stable on lomitapide who need to add atorvastatin, one of the following two regimens may be used: take the two medications 12 hours apart; or reduce the lomitapide dose by half (maintain the original dose for those taking 5 mg).

(2) After discontinuing atorvastatin, the lomitapide dose may be increased again as needed.

2. Co-administration with Other Weak CYP3A4 Inhibitors

(1) When taking other weak CYP3A4 inhibitors, lomitapide and the inhibitor should be taken 12 hours apart.

(2) Extra caution is needed when using multiple weak CYP3A4 inhibitors concurrently.

3. Co-administration with Bile Acid Sequestrants

If taking bile acid sequestrants such as colesevelam or cholestyramine, take them at least four hours before or at least four hours after taking lomitapide to avoid affecting drug absorption.

4. Mild Hepatic Impairment

In patients with mild hepatic impairment (Child-Pugh Class A), the daily dose should not exceed 40 mg.

5. End-Stage Renal Disease

In patients with end-stage renal disease on dialysis, the daily dose should not exceed 40 mg.

6. Elderly Patients

Because the recommended regimen starts with a low dose and increases gradually based on individual tolerability, no separate dose adjustment is recommended for elderly patients.

7. Overdose Management

In case of overdose, provide symptomatic support and necessary adjunctive treatment, and monitor liver function parameters.